Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8176 to 8190 of 8910 results

  1. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    Discontinued Reference number: GID-TA11401

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Discontinued Reference number: GID-TA11093

    Technology appraisal guidance
    Discontinued

  3. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    Discontinued Reference number: GID-TA11433

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    Discontinued Reference number: GID-TA11163

    Technology appraisal guidance
    Discontinued

  5. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    Discontinued Reference number: GID-TA10568

    Technology appraisal guidance
    Discontinued

  6. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    Discontinued Reference number: GID-TA11089

    Technology appraisal guidance
    Discontinued

  7. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    Discontinued Reference number: GID-TA11302

    Technology appraisal guidance
    Discontinued

  8. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    Discontinued Reference number: GID-TA11007

    Technology appraisal guidance
    Discontinued

  9. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued Reference number: GID-HST10019

    Highly specialised technologies guidance
    Discontinued

  10. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  11. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued

  12. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004

    Highly specialised technologies guidance
    Discontinued

  13. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development Reference number: GID-HST10037 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  14. OraQuick® HCV Rapid Antibody Test (discontinued)

    Discontinued Reference number: GID-MT117

    Medical technologies guidance
    Discontinued

  15. Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

    Discontinued Reference number: GID-MT163

    Medical technologies guidance
    Discontinued